Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
Multicentric, Non-Randomized Phase 2 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
  • Phase

    Phase 2
  • Study Type

  • Status

    Completed No Results Posted
  • Study Participants

The aim of the study is to assess the therapeutic activity and safety of the combination of Bendamustine and Rituximab in MALT lymphomas.

Primary endpoint:

Event-free-survival (EFS) (failure or death from any cause) for all patients.

Secondary endpoints:

Complete and partial remission rates for all patients
Response duration (time to relapse or progression) for responder patients
Progression-free-survival (PFS) (disease progression or death from lymphoma: for all patients
Overall survival for all patients
Acute and long-term toxicity
Study Started
May 31
Primary Completion
Dec 31
Study Completion
Dec 31
Last Update
Sep 07

Drug Rituximab and Bendamustine

Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2

Rituximab and Bendamustine Experimental


Inclusion Criteria:

Histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT type arisen at any extranodal site (WHO classification)
Any stage (Ann Arbor I-IV)

The novo disease en any extranodal site. For primary gastric or cutaneous lymphoma, local/specific previous treatment is accepted, just following the below criteria:

Cutaneous lymphoma: recurrent lymphoma after local therapy
Gastric lymphoma:

b1. H. pylori-negative cases, either de novo (non pre-treated) or at relapse following local therapy (i.e., surgery, radiotherapy or antibiotics).

b2. H. pylori-positive cases at diagnosis, who failed antibiotic therapy, including patients with: clinical (endoscopic) and histological evidence of disease progression at any time post H. pylori eradication; stable disease with persistent lymphoma at 1 year post H. pylori eradication; relapse (without H. pylori re-infection), after a remission; patients who failed either first line antibiotics or further local treatment (surgery or radiotherapy)

No evidence of histologic transformation to a high grade lymphoma
Measurable or evaluable disease
Age >18 and <85
ECOG performance status 0-2
Life expectancy of at least 1 year
Written informed consent given according to national/local regulations

Exclusion Criteria:

Prior chemotherapy or prior immunotherapy with any anti-CD20 monoclonal antibody
Prior radiotherapy in the last 6 weeks
Corticosteroids during the last 28 days, unless prednisone chronically administered at a dose <20 mg/day for indications other than lymphoma or lymphoma-related symptoms
Major impairment of renal function (serum creatinine > 2,5 x upper normal) or liver function (ASAT/ALAT <2,5 x upper normal, total bilirubin <2,5x upper normal), unless due to lymphoma involvement.
Impairment of bone marrow function (WBC <3.0x109/L, ANC <1.5x109/L, PLT <100x109/L), unless due to lymphoma involvement
Evidence of clinically significant cardiac, neurological or metabolic disease, unless due to lymphoma involvement
Evidence of symptomatic central nervous system (CNS) disease
Active HBV and/or HCV infection
Known HIV infection
Prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer
Any psychiatric disease potentially hampering compliance with the study protocol and follow-up schedule
Potential to attend regular visits to the hospital, on an outpatient regimen
Hypersensibility to any compound of the study medication.
Non appropriate contraceptive method in women of childbearing potential or men
Treatment with any drug under research within 30 days previous to start the study medication.
No Results Posted